MDVN Overview
Upcoming Projects (MDVN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MDVN)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (MDVN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MDVN)
-
FDA Accepts for Review sNDA for Label Modification to Prostate Cancer Treatment XTANDI, PDUFA Date is October 22, 2016
Ticker: MDVN
Occurred on: Oct 21, 2016 -
Medivation and Astellas Initiate Phase III Trial of Enzalutamide in Patients With Triple-Negative Breast Cancer
Tickers: MDVN, ALPMY
Occurred on: Jun 02, 2016 -
CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI (Enzalutamide)
Ticker: MDVN
Occurred on: Apr 07, 2016 -
FDA Releases Partial Clinical Hold on Pidilizumab - Phase 2 Trial Will Resume H2 of 2016
Ticker: MDVN
Occurred on: Mar 09, 2016 -
Phase 2 TERRAIN Trial of enzalutamide Compared to bicalutamide in Metastatic Castration-Resistant Prostate Cancer achieved its primary endpoint
Tickers: MDVN, TSE:4503, ALPMY
Occurred on: Jan 13, 2016 -
Medivation Initiates Pivotal Clinical Trial of MDV9300 (pidilizumab) in Diffuse Large B-Cell Lymphoma
Ticker: MDVN
Occurred on: Dec 21, 2015
Strategic Initiatives (MDVN)
-
Pfizer near $14 billion acquisition of Medivation
Tickers: PFE, MDVN
Announcement Date: Aug 21, 2016 -
NanoString Technologies Enters Into Collaboration Agreement With Medivation and Astellas to Develop Novel Companion Diagnostic Test
Tickers: NSTG, MDVN
Announcement Date: Jan 07, 2016
